AU2020337444A1 - Compositions and methods of treating vascular diseases - Google Patents

Compositions and methods of treating vascular diseases Download PDF

Info

Publication number
AU2020337444A1
AU2020337444A1 AU2020337444A AU2020337444A AU2020337444A1 AU 2020337444 A1 AU2020337444 A1 AU 2020337444A1 AU 2020337444 A AU2020337444 A AU 2020337444A AU 2020337444 A AU2020337444 A AU 2020337444A AU 2020337444 A1 AU2020337444 A1 AU 2020337444A1
Authority
AU
Australia
Prior art keywords
meso
mir
hsa
cells
vpcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020337444A
Other languages
English (en)
Inventor
Robert Lanza
Maria Mirotsou
Nutan PRASAIN
Amrita Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Astellas Institute for Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Institute for Regenerative Medicine filed Critical Astellas Institute for Regenerative Medicine
Publication of AU2020337444A1 publication Critical patent/AU2020337444A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2020337444A 2019-08-28 2020-08-27 Compositions and methods of treating vascular diseases Pending AU2020337444A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962892724P 2019-08-28 2019-08-28
US62/892,724 2019-08-28
PCT/US2020/048076 WO2021041591A1 (en) 2019-08-28 2020-08-27 Compositions and methods of treating vascular diseases

Publications (1)

Publication Number Publication Date
AU2020337444A1 true AU2020337444A1 (en) 2022-03-24

Family

ID=72428364

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020337444A Pending AU2020337444A1 (en) 2019-08-28 2020-08-27 Compositions and methods of treating vascular diseases

Country Status (13)

Country Link
US (1) US20220288131A1 (https=)
EP (1) EP4022038A1 (https=)
JP (2) JP2022545737A (https=)
KR (1) KR20220049618A (https=)
CN (1) CN115003794A (https=)
AU (1) AU2020337444A1 (https=)
BR (1) BR112022003659A2 (https=)
CA (1) CA3151636A1 (https=)
IL (1) IL290891A (https=)
MX (1) MX2022002418A (https=)
PH (1) PH12022550392A1 (https=)
TW (1) TW202122573A (https=)
WO (1) WO2021041591A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697641A (zh) 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂
EP4372079A4 (en) * 2021-07-15 2025-07-30 Astellas Pharma Inc PERICYTE-LIKE CELLS EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AT A HIGH LEVEL
CN114231481B (zh) * 2021-12-21 2023-07-18 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法
US20240228975A9 (en) * 2022-07-19 2024-07-11 Lung Biotechnology Pbc Methods for Differentiating Endothelial Cells
CN118177150B (zh) * 2024-04-15 2024-12-03 中国医学科学院医学实验动物研究所 遗传多样性高血压小鼠模型的建立与基因转录调控分析

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434527A (zh) 2006-04-14 2017-02-22 安斯泰来再生医药协会 血管瘤集落形成细胞
CA3186451A1 (en) * 2008-05-06 2009-11-12 Astellas Institute For Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
WO2010001375A1 (en) * 2008-06-30 2010-01-07 University College Cork, National University Of Ireland, Cork Primitive vascular progenitor cells and uses thereof
US20110305672A1 (en) * 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
US20140045265A1 (en) * 2011-02-16 2014-02-13 Salk Institute For Biological Studies Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors
RU2618871C2 (ru) * 2011-06-09 2017-05-11 Ф. Хоффманн-Ля Рош Аг Способ дифференциации плюрипотентных стволовых клеток в клетки сосудистого русла
WO2013069661A1 (ja) * 2011-11-08 2013-05-16 国立大学法人名古屋大学 iPS細胞由来血管前駆細胞シート及びその作製方法
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
WO2015153586A1 (en) * 2014-03-31 2015-10-08 The Johns Hopkins University Pluripotent stem cell therapies for ischemic retinopathies
GB201408712D0 (en) * 2014-05-16 2014-07-02 Univ Leuven Kath Mesodermal progenitor cells
SG11201706706XA (en) * 2015-02-20 2017-09-28 Wisconsin Alumni Res Found Generating arterial endothelial cell populations
WO2016185457A1 (en) * 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
JP6531335B2 (ja) * 2015-07-17 2019-06-19 国立大学法人京都大学 血管内皮細胞の誘導方法
JP6646311B2 (ja) * 2015-07-17 2020-02-14 国立大学法人京都大学 多能性幹細胞から中胚葉前駆細胞および血液血管前駆細胞への分化誘導法
CN108697641A (zh) 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂
WO2018031404A1 (en) * 2016-08-10 2018-02-15 Indiana University Research And Technology Corporation Method for generating mesoderm and/or endothelial colony forming cell-like cells having in vivo blood vessel forming capacity
WO2019152483A1 (en) * 2018-01-30 2019-08-08 University Of Georgia Research Foundation, Inc. Methods for vascular construction and products therefrom

Also Published As

Publication number Publication date
JP2022545737A (ja) 2022-10-28
KR20220049618A (ko) 2022-04-21
TW202122573A (zh) 2021-06-16
BR112022003659A2 (pt) 2022-05-24
WO2021041591A1 (en) 2021-03-04
CA3151636A1 (en) 2021-03-04
MX2022002418A (es) 2022-03-22
PH12022550392A1 (en) 2022-12-19
CN115003794A (zh) 2022-09-02
IL290891A (en) 2022-04-01
JP2026001090A (ja) 2026-01-06
US20220288131A1 (en) 2022-09-15
EP4022038A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
US20220288131A1 (en) Compositions and methods of treating vascular diseases
JP7333271B2 (ja) 心筋細胞の成熟および生着を増強するための方法および組成物
Gargett et al. Endometrial reconstruction from stem cells
CN101589137B (zh) 羊膜来源的细胞组合物及其制备方法和用途
US9938503B2 (en) Differentiation of human iPS cells to human alveolar type II via definitive endoderm
JP4085062B2 (ja) 霊長類の胚性幹細胞から由来した内皮細胞
HK1216235A1 (zh) 使用产後衍生细胞治疗外周血管疾病
AU2011299327B2 (en) Tissue-specific differentiation matrices and uses thereof
WO2006040755A2 (en) Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
US20120295347A1 (en) Methods and Compositions for Producing Endothelial Progenitor Cells from Pluripotent Stem Cells
US20080194023A1 (en) Generating vascular smooth muscle cells in vitro from ES cells
US20150064141A1 (en) Regenerative sera cells and mesenchymal stem cells
CN118497104A (zh) 胰岛细胞制备性组合物和使用方法
Yu et al. Construction of tissue engineered skin with human amniotic mesenchymal stem cells and human amniotic epithelial cells.
KR101574659B1 (ko) 인간 다능성 줄기세포로부터의 인슐린 생산 베타 세포의 내분비 응집체의 제조 방법
KR20240042354A (ko) 생착 및 재생능 강화를 위한 장 오가노이드 주변 기질 세포층 및 이의 용도
EP4428227A1 (en) Production method for sheet-like retinal tissue
RU2843942C2 (ru) Композиции и способы лечения сосудистых заболеваний
US20110076254A1 (en) Porous scaffolds for stem cell renewal
Pilling Conversion of human fibroblasts to endothelial-like cells via dedifferentiation to mesodermal progenitors in 3D condensates
AU2008202264A1 (en) Novel Methods for the In-Vitro Indentification, Isolation and Differentiation of Vasculogenic Progenitor Cells
AU2004220699A1 (en) Novel Methods for the In-Vitro Identification, Isolation and Differentiation of Vasculogenic Progenitor Cells